Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers.
Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed …

Conventional cytotoxic chemotherapy used to treat acute lymphoblastic leukemia (ALL)
results in high cure rates in pediatric patients but is suboptimal in the treatment of adult …

Background Outcomes in patients with Philadelphia chromosome (Ph)–positive acute
lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors …

The estimated overall incidence of acute lymphoblastic leukaemia (ALL) and lymphoblastic
lymphoma in Europe is 1.28 per 100 000 individuals annually, with significant age-related …

In this study, we randomly compared high doses of the tyrosine kinase inhibitor imatinib
combined with reduced-intensity chemotherapy (arm A) to standard imatinib/hyperCVAD …

Significant advances have been made in the last decade toward a better understanding of
the disease pathogenesis and the development of novel therapies that target specific …

Background Combination of chemotherapy with a tyrosine-kinase inhibitor is effective in the
treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia. Ponatinib is …

The Philadelphia chromosome positive arm of the UKALLXII/ECOG2993 study for adult
acute lymphoblastic leukemia (ALL) enrolled 266 patients between 1993 and 2003 (pre …

Although acute lymphoblastic leukemia is curable in one third of adult patients, results vary
greatly on account of different clinical, immunologic, and cytogenetic/genetic characteristics …

Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute
Lymphoblastic Leukemia: A Children's Oncology Group Study - PMC Back to Top Skip to main …